CPO301
Antibody–drug conjugate
Also known as SYS6010
Evidence outlook
Non-Small Cell Lung Cancer: topline reported 2026-08-26
The sponsor reported topline results on 2026-08-26 (Phase 3 SYNSTAR01 (NCT06927986) of SYS6010 met its pre-specified PFS primary endpoint at interim analysis). The announcement is listed under Regulatory events.
Latest reported trial: NCT06927986 · Phase 3 · met primary endpoint · grade pending
Also in development:Head and Neck Squamous Cell Carcinoma · Phase 3Breast Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06927986 NCT06927986 · EGFR-mutated Locally Advanced or Metastatic NSCLC Registry: NCT06927986 | 3 | Progression-free survival (PFS) assessed by independent review committee (IRC) (Up to approximately 1.5 years) 2026-07-30 | In progress: primary completion was expected 30 Jul 2026; results not posted | not yet graded | link ↗ |
View 3 more trials
SYNSTAR-02 NCT07376382 · NSCLC Registry: NCT07376382 | 3 | Progression Free Survival(PFS) evaluated by IRC (Up to 3.5 years) 2026-12-12 | In progress: results expected 12 Dec 2026 | not yet graded | link ↗ |
SYNSTAR03 NCT07442565 · Non-Small Cell Lung Cancer Registry: NCT07442565 | 3 | PFS (Progression-Free Survival) assessed by IRC (Independent Review Committee) in the EGFR high-expression population. (Up to approximately 22 months); OS (Overall Survival) in the overall population (Up to approximately 39 months) 2027-12-30 | In progress: results expected 30 Dec 2027 | not yet graded | link ↗ |
NCT07672223 NCT07672223 · Non-small Cell Lung Cancer Registry: NCT07672223 | 3 | Disease-Free Survival (DFS) assessed by the independent review committee (IRC) (Up to approximately 60 months) 2029-09-30 | In progress: results expected 30 Sept 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other EGFR drugs
Cetuximab, Erlotinib, Gefitinib, Lazertinib, Osimertinib and 36 more. Compare all 42 EGFR drugs
This mechanism is crowded: 41 other tracked programmes target it, 6 of them ahead of this one.
This drug's own stage for Head and Neck Squamous Cell Carcinoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| CPO301: this drug | Phase 3 | Antibody–drug conjugate | EGFR | not yet graded | No reviewed efficacy summary in this indication | |
| Cetuximab | Approved | Monoclonal antibody | EGFR | Partial signal | NCT00122460: Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3) | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02105636: Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05) | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02358031: Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048). | |
| Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj) | Approved | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Amivantamab | Phase 3 | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| NBTXR3 | Phase 3 | Nanoparticle | Hafnium-oxide nanoparticle radioenhancer | not yet graded | No reviewed efficacy summary in this indication | |
| Volrustomig | Phase 3 | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Ordastobart | Phase 2/3 | Monoclonal antibody | OX40 (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab | Phase 2 | Multispecific antibody | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Ozuriftamab Vedotin | Phase 2 | Antibody–drug conjugate | ROR2 | Partial signal | No reviewed efficacy summary in this indication | |
| ALE.P02 | Phase 1/2 | Antibody–drug conjugate | Claudin-1 (CLDN1) | not yet graded | No reviewed efficacy summary in this indication | |
| Pepinemab | Phase 1/2 | Monoclonal antibody | SEMA4D | not yet graded | No reviewed efficacy summary in this indication | |
| Buparlisib | Discontinued | Small molecule | PI3K inhibitor (pan-class I) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
12 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(17 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow CPO301 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (6)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
September 2027 (1)
What to watch
October 2027 (1)
What to watch
2028 (3)
June 2028 (1)
What to watch
September 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (6)
February 2029 (1)
What to watch
April 2029 (1)
What to watch
September 2029 (1)
What to watch
October 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent